Advertisement

Sphingomyelinase and Niemann-Pick Disease

  • Marie T. Vanier
  • Robert Rousson
  • Randa Zeitouni
  • Peter G. Pentchev
  • Pierre Louisot
Part of the NATO ASI Series book series (NSSA, volume 116)

Abstract

Niemann-Pick disease (NPD) is the name given to a group of genetic disorders in which the common feature is a varying degree of sphingomyelin storage in certain tissues. The wide range of clinical heterogeneity led Crocker to suggest in 1961 a classification into four types, A to D, which is still widely used. Schematically, type A refers to cases similar to the original description of Albert Niemann, i.e. an infantile severe neurovisceral form. Patients presenting with a heavy visceral involvement but no neurological symptoms are assigned to type B. In those two types, a severe and generalized deficiency of sphingomyelinase activity has been desmonstrated (for review, see Brady, 1983). There is more confusion for classification of a third group of patients with neurovisceral involvement but a protracted neurological onset, originally subdivided by Crocker into types C and D, and also described in the litterature under other names, among which juvenile NPD, juvenile dystonic lipidosis, neurovisceral disease with vertical supranuclear ophtalmoplegia. In this group, the nature of the primary biochemical lesion remains unknown. None of the postulated defects, lack of a specific sphingomyelinase isoenzyme (Callahan et al., 1974) or of an activator (Christomanou, 1980) has to-date received general acceptance, and it is not even clear at present if such patients belong to a single nosological entity or not. For the sake of simplification, the name NPD type C will be used throughout the present report for designation of the group as a whole.

Keywords

Skin Fibroblast Anionic Phospholipid Culture Skin Fibroblast Liposomal System Sphingomyelinase Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Albouz, S., Hauw, J.J., Berwald-Netter, Y., Boutry, J.M., Bourdon, R.,and Baumann, N., 1981, Tricyclic antidepressants induce sphingomyelinase deficiency in fibroblasts and neuroblastoma cell cultures, Biomedicine, 35: 218–220.PubMedGoogle Scholar
  2. Basu, A. and Glew, R.H., 1984, Characterization of the phospholipid re- quirement of a rat liver β-glucosidase, Biochem.J., 224: 515–524.PubMedGoogle Scholar
  3. Beaudet, A.L. and Manschrek, A.A., 1982, Metabolism of sphingomyelin by intact cultured fibroblasts. Differentiation of Niemann-Pick disease type A and B, Biochem.Biophys.Res.Commun., 105: 1419.CrossRefGoogle Scholar
  4. Berent, S.L. and Radin, N.S., 1981, β-Glucosidase activator protein from bovine spleen (coglucosidase), Arch.Biochem.Biophys., 208: 248–260.PubMedCrossRefGoogle Scholar
  5. Besley, G.T.N., Hoogeboom, A.J.M., Hoogeven, A., Kleijer, W.J. and Galjaard, H., 1980, Somatic cell hybridization studies showing different gene mutations in Niemann-Pick disease variants, Hum.Genet., 54: 409–412.PubMedCrossRefGoogle Scholar
  6. Brady, R.O., 1983, Sphingomyelin lipidoses: Niemann-Pick disease. In “The Metabolic Basis of Inherited Disease,” J.B. Stanbury, J.B. Wyngaarden, D.S. Fredrickson, J.L. Goldstein, M.S. Brown, eds., Mc Graw Hill, New York, pp. 831–841.Google Scholar
  7. Callahan, J.W., Khalil, M., Gerrie, J., 1974, Isoenzymes of sphingomyelinase and the genetic defect in Niemann-Pick disease, Biochem.Biophys.Res.Commun., 58: 384–390.CrossRefGoogle Scholar
  8. Christomanou, H., 1980, Niemann-Pick disease type C: evidence for the deficiency of an activating factor stimulating sphingomyelin and glucocerebroside, Hoppe Seyler’s Z.phys.Chem., 361: 1489–1502.CrossRefGoogle Scholar
  9. Christomanou, H. and Kleinschmidt, T., 1985, Isolation of two forms of an activator protein for the enzymic sphingomyelin degradation from human Gaucher spleen, Biol.Chem.Hoppe-Seyler, 346: 245–256.CrossRefGoogle Scholar
  10. Dale, G.L., Villacorte, D.G. and Beutler, E., 1976, Solubilization of glucocerebrosidase from human placenta and demonstration of a phospholipid requirement for its catalytic activity, Biochem.Biophys.Res. Commun., 71: 1048–1053.PubMedCrossRefGoogle Scholar
  11. Fujibayashi, S. and Wenger, D.A., 1985, Studies on a sphingolipid activator protein (SAP-2) in fibroblasts from patients with lysosomal storage diseases, including Niemann-Pick disease type C, Clin.Chim.Acta, 146: 147–156.PubMedCrossRefGoogle Scholar
  12. Gatt, S., Herzl, A. and Barenholz, Y., 1973, Hydrolysis of sphingomyelin liposomes by sphingomyelinase, Febs Lett., 30: 281–285.PubMedCrossRefGoogle Scholar
  13. Hanada, E. and Suzuki, K., 1979, Activation of human brain galactosylceramidase by phosphatidylserine, Biochim.Biophys.Acta, 575: 410–420.PubMedCrossRefGoogle Scholar
  14. Ho, M.W. and Light, M, 1973, Glucocerebrosidase: reconstitution from macromolecular components depends on acidic phospholipids, Biochem.J., 136: 821–823.PubMedGoogle Scholar
  15. Kudoh, T., Velkoff, M. and Wenger, D.A., 1983, Uptake and metabolism of radioactively labelled sphingomyelin in cultured skin fibroblasts from controls and patients with Niemann-Pick disease and other lysosomal diseases, Biochim.Biophys.Acta, 754: 82–92.PubMedCrossRefGoogle Scholar
  16. Pentchev, P.G., Gal, A.E., Boothe, A.D., Omodeo-Sale, F., Fouks, J., Neumeyer, B.A., Quirk, J.M., Dawson,G. and Brady, R.O., 1980, A lysosomal storage disorder in mice characterized by a dual deficiency of sphingomyelinase and glucocerebrosidase, Biochim.Biophys.Acta, 619: 669–679.PubMedCrossRefGoogle Scholar
  17. Pentchev, P.G., Boothe, A.D., Kruth, H.S., Weintroub, H., Stivers, J. and Brady, R.O., 1984, A genetic storage disorder in BALB/C mice with a metabolic block in esterification of exogeneous cholesterol, J.Biol.Chem., 259: 5784–5791.PubMedGoogle Scholar
  18. Pentchev, P.G., Comly, M.E., Kruth, H.S., Vanier, M.T., Wenger, D.A., Patel, S. and Brady, R.O., 1985, A defect in cholesterol esterification in certain patients designated as Niemann-Pick disease type C. Proc. Nat.Acad.Sci.USA, in press.Google Scholar
  19. Peters, S.P., Coyle, P., Coffee, C.J., Glew, R.H., Kuhlenschmidt, M.S., Rosenfeld, L. and Lee, Y.C., 1976, Purification and properties of a heat-stable glucocerebrosidase activating factor from control and Gaucher spleen. J.Biol.Chem., 252: 563–573.Google Scholar
  20. Poulos, A., Shankaran, P., Jones, C.S. and Callahan, J.W., 1983, Enzymatic hydrolysis of sphingomyelin liposomes by normal tissues and tissues from patients with Niemann-Pick disease, Biochim.Biophys.Acta, 751: 428.PubMedCrossRefGoogle Scholar
  21. Poulos, A., Ranieri, E., Shankaran, P. and Callahan, J.W., 1984a, Studies on the activation of the enzymatic hydrolysis of sphingomyelin liposomes, Biochim.Biophys.Acta, 793: 141–148.PubMedCrossRefGoogle Scholar
  22. Poulos, A., Ranieri, E., Shankaran, P. and Callahan, J.W., 1984b, Studies on the activation of sphingomyelinase activity in Niemann-Pick type A, B and C fibroblasts. Enzymological differentiation of type A and B, Ped.Res., 18: 1088–1093.CrossRefGoogle Scholar
  23. Rousson, R., Vanier, M.T. and Louisot, P., 1983, Chromatofocusing of purified placental sphingomyelinase, Biochimie, 65: 115–120.PubMedCrossRefGoogle Scholar
  24. Vanier, M.T., 1983, Biochemical studies in Niemann-Pick disease.I-Major sphingolipids of liver and spleen, Biochim.Biophys.Acta, 750: 178. 184Google Scholar
  25. Vanier, M.T. and Rousson, R., 1984, Niemann-Pick disease:a clinical and biochemical study, In “Recent Progress in Neurolipidoses and Allied Disorders,” M.T.Vanier, ed., Fondation Mérieux, Lyon, pp. 183–201.Google Scholar
  26. Vanier, M.T., Revol, A. and Fichet, M., 1980, Sphingomyelinase activities of various human tissues in control subjects and in Niemann-Pick disease, Clin.Chim.Acta, 106: 257–267.PubMedCrossRefGoogle Scholar
  27. Vanier, M.T., Rousson, R., Garcia, I., Bailloud, G., Juge, M.C., Revol, A. and Louisot, P., 1985, Biochemical studies in Niemann-Pick disease.III-In vitro and in vivo assays of sphingomyelin degradation in cultured skin fibroblasts and amniotic fluid cells for the diagnosis of the various forms of the disease, Clin.Genet., 27: 20–32.PubMedCrossRefGoogle Scholar
  28. Wenger, D.A., Sattler, M. and Roth, S., 1982, A protein activator of galactosylceramide β-galactosidase, Biochim.Biophys.Acta, 712: 639–649.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • Marie T. Vanier
    • 1
    • 2
  • Robert Rousson
    • 1
  • Randa Zeitouni
    • 2
  • Peter G. Pentchev
    • 3
  • Pierre Louisot
    • 1
  1. 1.Laboratoire de Biochimie, Faculté de Médecine Lyon-SudINSERM U 189Oullins CedexFrance
  2. 2.Laboratoire de NeurochimieFondation Gillet-Mérieux Centre Hospitalier Lyon-SudPierre BéniteFrance
  3. 3.Developmental and Metabolic Neurology BranchNINCDS National Institutes of HealthBethesdaUSA

Personalised recommendations